

VU Research Portal

Cognition in centenarians

Beker, N.

2020

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

Beker, N. (2020). *Cognition in centenarians: Evaluation of cognitive health in centenarians from the 100-plus Study*. [PhD-Thesis - Research and graduation internal, Vrije Universiteit Amsterdam].

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl



Associations between cognitive functions,
pathological hallmarks and physical health



Chapter

5

Neuropathology and cognitive performance in self- reported cognitively healthy centenarians

Andrea B. Ganz
Nina Beker
Marc Hulsman
Sietske A.M. Sikkes
Netherlands Brain Bank
Philip Scheltens
August B. Smit
Annemieke J. M. Rozemuller
Jeroen J. M. Hoozemans
Henne Holstege

ABSTRACT

With aging, the incidence of neuropathological hallmarks of neurodegenerative diseases increases in the brains of cognitively healthy individuals. It is currently unclear to what extent these hallmarks associate with symptoms of disease at extreme ages. Forty centenarians from the 100-plus Study cohort donated their brain. Centenarians self-reported to be cognitively healthy at baseline, which was confirmed by a proxy. Objective ante-mortem measurements of cognitive performance were associated with the prevalence, distribution and quantity of age- and AD-related neuropathological hallmarks. Despite self-reported cognitive health, objective neuropsychological testing suggested varying levels of ante- mortem cognitive functioning. Post-mortem, we found that neuropathological hallmarks related to age and neurodegenerative diseases, such as A β and Tau pathology, as well as atherosclerosis, were abundantly present in most or all centenarians, whereas Lewy body and pTDP-43 pathology were scarce. We observed that increased pathology loads correlated across pathology subtypes, and an overall trend of higher pathology loads to associate with a lower cognitive test performance. This trend was carried especially by the presence of neurofibrillary tangles (NFTs) and granulovacuolar degeneration (GVD) and to a lesser extent by A β -associated pathologies. Cerebral Amyloid Angiopathy (CAA) specifically associated with lower executive functioning in the centenarians. In conclusion, we find that while the centenarians in this cohort escaped or delayed cognitive impairment until extreme ages, their brains reveal varying levels of disease-associated neuropathological hallmarks, some of which associate with cognitive performance.

INTRODUCTION

The increase in average life expectancy warrants insight into healthy aging. In particular, the study of centenarians might reveal new leads towards healthy aging and potential clues to overcome age-related diseases. Alzheimer's disease (AD) is the most common age-related neurodegenerative disease for which increasing age is the most important risk factor. The prevalence of AD is estimated to double every 5 years after the age of 65, resulting in a population prevalence of roughly 40% for western Europeans aged 90 years and older [11, 31, 35]. The two most prominent neuropathological hallmarks of AD are (1) the intracellular accumulation of hyperphosphorylated Tau protein (pTau) in Neurofibrillary tangles (NFTs) and (2) the accumulation of extracellular Amyloid- β (A β) fibrils into senile plaques [27, 33]. Additional AD-associated neuropathological changes are: neuritic plaques (NPs), where A β plaques and dystrophic neurites occur in the same structures, cerebral amyloid angiopathy (CAA), characterized by the deposition of A β in the endothelial cells of blood vessels, and granulovacuolar degeneration (GVD), which is characterized by the accumulation of stress proteins in intracellular granules. Whereas Lewy body and phosphorylated TDP-43 (pTDP-43) proteinopathies are usually associated with other neurodegenerative diseases, they often are also observed in late-onset AD cases [42].

Clinicopathologic correlation studies revealed that the severity of cognitive impairment in AD correlates best with the burden of neocortical NFTs [31]. The presence of A β is a prerequisite for AD and may catalyze the pathological process that ultimately leads to clinical [42]. However, the concurrent accumulation of individual pathologies, like CAA, GVD, LB, and pTDP-43, may have an additive effect on the rate of cognitive decline, and contribute to the apparent decrease of the association between NFTs, A β and dementia symptoms in older ages [42]. Brains of older dementia patients commonly show less NFT and A β pathology compared to younger AD patients [9, 17, 18, 38]. This suggests that, while disease-associated proteinopathies distinguish well between brains from young AD cases and age-matched non-demented controls, this appears more complicated for brains from older individuals. So far, post-mortem brain assessments of cognitively healthy individuals who reached > 110 years revealed various results: some cognitively healthy centenarians did not accumulate significant pathology, while others appeared to have relatively high levels of pathology [13, 32, 43].

Strengths and weaknesses, and the unique aspects of the 100-plus Study

Ideally, to assess the unique aspects of maintained cognitive health during extreme longevity, one would like to assess brain tissues of cognitively healthy centenarians from individuals who were recruited at much younger ages and followed up until death, i.e. in the context of a longitudinal population study. However, this is complicated as only a small subset of individuals reaches ages older than 100 and of these, only a small subset remains cognitively healthy. To overcome this problem, most studies collected tissues retrospectively, and often, no extensive and consistent set of neuropsychological measurements before death is available [6, 12–14, 16, 20]. Furthermore, we found that most studies dichotomize the disease label (case or control) based on post-mortem findings or on neuropsychological assessments and/or clinical diagnosis of dementia (e.g. CDR scale), that were collected relatively long prior to death [2, 4, 6, 10, 13, 16, 17, 19, 21, 25]. Some studies provide only (semi-) quantitative scores of selected hallmarks in selected brain regions [8, 9, 15]. Together, this complicates the neuropathological assessment of resilience against cognitive decline despite extreme longevity [6, 12–14, 16, 20].

In the 100-plus Study, we focus specifically on this aspect by including only cognitively healthy centenarians in our cohort [19]. The longitudinal set-up of our study allows us to focus specifically on the neuropsychological changes prior to death and the levels and distribution of neuropathology throughout the brain. For this, a unique aspect of the 100-plus Study is the longitudinal administering of a comprehensive set of neuropsychological tests between 100 years and death. After death, we invest in a complete characterization of brain tissues, using an elaborate set of neuropathological hallmarks across several brain areas. The 100-plus Study is relatively young, and while 91 centenarians have agreed to post-mortem brain donation, we can now present the initial data of the first 40 brains.

The aim of this study is to investigate how neuropathological changes relate with performance on neuropsychological tests in centenarians. Prospective neuropsychological testing of these individuals allowed us to correlate ante-mortem cognitive functioning of selected tests with the occurrence of pathological hallmarks of neurodegenerative diseases in the post-mortem brain. For this, we focused on inclusions of pTau as NFTs [4] and aging-related tau astroglialopathy (ARTAG) [24]; the distribution of A β protein as diffuse [46], classical or NPs [26], and CAA [45]; the distribution of casein kinase 1 delta (CK1 δ) as a marker of GVD [44]; and the distribution of Lewy bodies [7] and pTDP-43 accumulations [28]. Furthermore, for an individual case, we report on the in-vivo assessment of pathology using an MRI and amyloid PET scan, and the occurrence of post-mortem neuropathological changes.

MATERIAL AND METHODS

100-plus Study cohort

The 100-plus Study is a prospective centenarian cohort study. Inclusion criteria for the study are, next to being able to provide proof of being 100 years or older, that centenarians “self-report to be cognitively healthy, which is confirmed by a proxy” [19]. Although it is not a requirement for study participation, almost 30% of all participants agree to post-mortem brain donation. Here we compare the ante- and post-mortem status of the first 40 participants of the 100-plus Study that came to autopsy. The 100-Plus Study was approved by the Medical Ethical Committee of the VU University Medical Center. Informed consent was obtained from all study participants. The detailed study protocol is described elsewhere [19].

Post-mortem brain autopsy procedures

Autopsies were performed in collaboration with the Netherlands Brain Bank (NBB, Amsterdam, The Netherlands). Brain weight was recorded, and we macroscopically determined levels of atrophy and atherosclerosis of the intracranial vessels. Atrophy was subjectively staged by an experienced neuropathologist according to severity (none (0), mild (1), moderate (2) or strong (3)). Atherosclerosis was scored as mild (1), if only some parts of the circle of Willis and the basal arteries were affected; moderate (2), if the circle of Willis and the basal arteries were severely affected and the arteria cerebri media was not affected beyond the first cm; and severe (3), if also the deeper part of the arteria cerebri media was affected. The right hemisphere of the brain was formalin fixed, and the left hemisphere was dissected and the pieces were snap frozen in liquid nitrogen.

Neuropathology: Immunohistochemistry

Neuropathological characterization of centenarian brains was performed by Haematoxylin and Eosin (H&E) stain, Gallyas silver stain [34, 48] and immunohistochemistry (IHC). For IHC, brain tissues were formalin fixed and paraffin embedded (FFPE), then sectioned into 6 μm slices and mounted on microscope slides (Leica Xtra adhesive slides, Leica Microsystems, Rijswijk, The Netherlands). After deparaffinization and rehydration, endogenous peroxidase activity was blocked in 0.3% H_2O_2 in phosphate buffered saline, pH 7.0 (PBS) for 30 min. Antigen retrieval was performed with heated sodium-citrate buffer (10 mM/L, pH 6.0). For the staining of α -synuclein, pre-treatment included only heated sodium citrate without endogenous peroxidase blocking. All primary antibodies were diluted in normal antibody diluent (Immunologic, VWR company, Duiven, The

Netherlands) (Table 1). Primary antibody incubation was performed overnight at 4 °C. Subsequently, sections were incubated with the EnVision detection system (goat anti-mouse/rabbit horseradish peroxidase (HRP), DAKO, Heverlee, Belgium) for 40 min at room temperature. Between incubation steps, sections were rinsed with PBS. Sections were incubated for 5 min with the chromogen 3,3'-diaminobenzidine (DAB, EnVision Detection system/HRP, DAKO, Heverlee, Belgium) to visualize immunoreactivity. Nuclei were counterstained with haematoxylin. Hereafter, slides were dehydrated and mounted using the non-aqueous mounting medium Quick-D (Klinipath, Duiven, The Netherlands). Negative controls were obtained by performing the same procedures while omitting the primary antibody.

Table 1. Overview of primary antibodies

| Antibody | Antigen | Species | Dilution (FFPE material) | Manufacturer |
|----------------|--|---------|--------------------------------|---|
| IC-16 | N-terminal amino acids 1-6 of the A β peptide | mouse | 1:800 | Kind gift of Prof. Dr. Korth, Heinrich Heine University, Düsseldorf, Germany [46] |
| AT-8 | Tau phosphorylated at Ser202 and Thr205 | mouse | 1:800 | Pierce Biotechnology, Rockford, IL, USA |
| CK16 | casein kinase 1 delta | mouse | 1:100 | Santa Cruz Biotechnology, Heidelberg, Germany |
| pTDP-43 | Transactive response DNA binding protein 43 | mouse | 1:8000 | Cosmo Bio, Tokyo, Japan |
| 18-0215 | alpha-synuclein | mouse | 1:200 | Zymed, Thermo Fisher Scientific, Bleiswijk, The Netherlands |

Neuropathological evaluation

Distribution of A β and pTau in NFTs and NPs was determined by immunohistochemical staining (IHC) with respectively IC-16 and AT-8 antibodies on the frontal cortex (F2), temporal pole cortex, parietal cortex (superior and inferior lobule), occipital pole cortex and the hippocampus (CA1 and entorhinal area of the parahippocampal gyrus). NFTs and NPs were identified using a combination of Gallyas silver staining and IHC for AT-8. A β distribution was evaluated according to the Thal staging ranging from 0 to 5 [47]. The temporal-spatial distribution of NFTs was evaluated according to the Braak stages ranging from 0 to VI [3–5]. NPs were evaluated according to CERAD scores ranging from 0 to 3 [26].

The presence of ARTAG was assessed using IHC for pTau in the frontal cortex (F2), temporal pole cortex, parietal cortex (superior and inferior lobule), occipital pole cortex and the hippocampus (CA1 and entorhinal area of the parahippocampal gyrus).

GVD was assessed by IHC using CK1 δ as a marker, and scored based on the staging system from Thal et al., 2011 (Thal stage GVD*) [44], ranging from 0 to 5. The presence of CK1 δ positive accumulations was assessed in the hippocampal areas CA1/Subiculum and CA4, entorhinal cortex, temporal pole cortex, amygdala, cingulate gyrus, frontal (F2) and parietal lobe. GVD stage was classified as 1, if only the subiculum and CA1 region of the hippocampal formation were affected. In stage 2, the CA4 and/or entorhinal cortex were additionally affected. Additional CK1 δ granules in the temporal pole cortex were classified as stage 3. Cases were scored as stage 4 if the amygdala was affected, but neither the cingulate gyrus or the frontal or parietal cortex were affected. If either cingulate gyrus, frontal cortex or parietal cortex showed additional depositions of CK1 δ , cases were classified as stage 5.

pTDP-43 pathology was assessed by IHC and stages ranged from 0 to 3 according to Nag et al., 2015 [28]. Immunohistochemistry with the pTDP-43 antibody was performed on slices of the amygdala (stage 1), hippocampal areas CA1/Subiculum and dentate gyrus, entorhinal cortex (stage 2), frontal and temporal pole cortex (stage 3), in which the presence of cytoplasmic inclusions was assessed.

Lewy body pathology was assessed according to Braak [2, 7] by IHC for α -synuclein in the hippocampus, amygdala, medulla oblongata, substantia nigra and locus coeruleus. For a case with high amounts of α -synuclein inclusions, the frontal and precentral gyrus were additionally assessed.

Neuropsychological tests and educational attainment

All study participants were visited at home by a trained researcher at baseline inclusion, and when available and willing, at yearly follow-up visits. During these visits, we objectively assessed cognitive functioning using an elaborate test battery described elsewhere [19]. Here we report the performance on the Mini-Mental State Examination (MMSE), Visual Association Test (VAT) and the Clock Drawing Test (CDT), as they are well known and often used for dementia screening. The MMSE is an 11-item test evaluating overall cognitive functioning with a scoring range of 0–30 (bad-good) [16]; missing items were imputed as described before [19], provided no more than 6 items were missing. The VAT is a test for episodic memory with a 0–12 (trial 1 +2) range (bad-good) [25], and the CDT is a test for visuospatial and executive functioning, with a 0–5 range (bad-good) [39, 40]. When sensory impairments, fatigue, or lack of motivation impeded test administration, no score

was reported (N/A). We report test scores at baseline and at last visit before death. For cases with only one visit, baseline- and last visit are the same. Number of visits and time between last visit and death per case is listed in Supplementary Table S1. Educational attainment was assessed by self-report and categorized according to the International Standard Classification of Education 1997 (ISCED) [49], as well as years of education.

Correlation of cognitive performance with post-mortem brain pathology

To determine whether performance on cognitive tests of centenarians correlated with post-mortem brain pathologies, we correlated pre-mortem neuropsychological test scores and demographic descriptives with levels of post-mortem neuropathological hallmarks of aging and disease. For this, we used MMSE, VAT and CDT test scores, both at baseline and last visit. A secondary measure of cognitive performance was “the ability to complete testing” as a proxy of fatigue or non-willingness; scores were 2 (all tests completed, or tests not applied due to sensory problems), 1 (MMSE completed, which was administered first, but not VAT and/or CDT), and 0 (no tests completed). After each study visit, the impression of cognitive health of the participant was subjectively estimated by a trained researcher as 0 (symptoms of impairment), 1 (possible symptoms of impairment), or 2 (no symptoms of impairment) (see [19] for protocol). The scored impression of cognitive health closest to death was used for analysis. ApoE genotypes were ranked according to their association with increased AD-risk (odds ratios) as reported previously [8]: E2/2 (OR 0.24); E2/3 (OR 0.5); E3/3 (OR 1.0); E2/4 (OR 3.2); E3/4 (OR 5.5), E4/4 (OR 20.6).

Education was categorized by years of formal education. Sex: female, 0; male, 1. As post-mortem characteristics of all 40 brains, we used brain weights, corrected for sex by linear regression and the levels of atrophy, atherosclerosis, scored as described above. For a subset of 35 brains, Thal stage GVD* and pTDP-43 staging was available, and for 26 brains Braak stage for Lewy bodies, Thal stage for CAA, Thal stage for A β , CERAD score for NPs, Braak stage for NFT distribution, infarct occurrence and hippocampal sclerosis presence was available. Overview of all variables is provided in Supplementary Tables S1 and S2.

Statistical analyses

Correlations between neuropsychological test performance and neuropathology were determined using Pearson correlation. We calculate Figueiredo p-values and false discovery rates (fdr) for all correlations (Additional file 3: Tables S3b and S3c). In Figure 3, strength of the Pearson correlation coefficient is indicated by the size

and color of each dot (Supplementary Table S3a), the *fdr* is indicated as asterisks (* < 20%, ** < 10%, *** < 5%). All calculations were performed in R (version 3.3) [36].

PET/MRI scan in case report

Scanning was performed 1 month after study inclusion for case 100069. The participant was injected with 383 MBq 11C-PIB. Sixty minutes after injection, dynamic images of the brain were captured on the Philips TF PET-MRI scanner in 6 frames of 5 min duration. Due to extensive movement, only the activity in the first frame could be used. The PET scan was visually assessed by an experienced nuclear medicine physician.

RESULTS

We analyzed brain tissue from 40 centenarians, (72.5% female), aged between 100 and 111 years (Supplementary Table S1).

Neuropathological characteristics in centenarian brains

The mean post-mortem interval for all 40 donated brains was 6h44min (range: 3.5–12 h). At autopsy the median brain weight was 1195 g (IQR 1060 g–1355 g) in males and 1115 g (IQR 965 g–1320 g) in females. ApoE genotypes were: E2/3 (15.8%), E3/3 (73.7%), E2/4 (5.3%), and E3/4 (7.9%). Full neuropathological characterization was present for 26 brains, partial characterization with staging for pTDP-43 stage and Thal stage GVD* was present for 35 cases. We observed varying levels of atherosclerosis in all 40 brains. Mild or moderate atrophy was present in 50% of all cases, while severe atrophy was not observed in any of the 40 brains. All 26 centenarian-brains with full neuropathological assessment revealed known age-related pathologies such as ARTAG [24] (Figure 1c and Supplementary Table S1), and were scored with high stages of GVD: only GVD stages between 3 and 5 were observed (Figure 1i). According to the NIA-AA guidelines, 8% of the centenarians had no AD-associated neuropathological changes, 42% had low neuropathological changes, 50% had intermediate changes, and none had high level of changes (Figure 1g). Levels of A β deposits cover all possible Thal stages (mean Thal stage for A β : 2.6). The NFT distribution ranged from Braak stage I to IV, (mean Braak stage: III). None of the centenarians had Braak stage 0, or Braak stage V or VI. The level of NPs ranged from CERAD scores 0 to 2, CERAD score 3 was not observed (mean CERAD score: 0.8). In 20 of the 26 centenarians we observed CAA pathology (77%, mean Thal stage for CAA: 1), always in combination with

A β plaques. We observed pTDP-43 pathology in 13 of 35 centenarians (37%, mean pTDP-43 stage: 0.9), and 5 cases showed additional hippocampal sclerosis (19.2%). Hippocampal sclerosis was exclusively observed in combination with pTDP-43 pathology (Additional file 1: Table S1). Lewy body pathology was observed in 4 of 26 cases (15.4%, mean Braak stage for Lewy bodies: 0.4), 3 of which co-occurred with pTDP-43 pathology. Despite high cognitive test performance (baseline score on the MMSE: 27), one case was clinically diagnosed with Parkinson's disease years before entering the study. The brain included many Lewy bodies at post-mortem neuropathological evaluation (Braak stage for Lewy bodies VI). Additionally, we detected infarcts in 14 (54%) of the 26 centenarians. Overall, the centenarians in our cohort showed moderate levels of AD related pathology. Centenarians rarely showed the highest score for any of the AD associated pathologies, with the exception of GVD. Overall scores for Lewy bodies and pTDP-43 appeared relatively low in centenarians.




Figure 1. Distribution and severities of pathology within the group of 26 centenarians. For atrophy and atherosclerosis, n=40. n=35 for Thal stage GVD* and pTDP-43 stage, for all other pathologies, n=26. Thal stage GVD* indicates an adapted staging system, see Methods section.

Performance on neuropsychological tests of 40 centenarian brain donors

The aim of this study is to investigate how neuropathological changes are associated with performance on neuropsychological tests in centenarians. The last visit occurred on average 10 ± 7 months prior to brain donation. 18 centenarians were available for at least one follow-up visit; follow-up for two additional centenarians was performed by questionnaire. Centenarians had a variable educational attainment (median years of education: 8, range 6 - 20y). MMSE, VAT and CDT scores were available for respectively 95, 67.5 and 65% of centenarians at baseline (Figure 2a). At last visit, MMSE, VAT and CDT scores were available for respectively 87.5, 57.5 and 52.5% of centenarians. The mean (\pm SD) score on the MMSE was 24 ± 4.5 at baseline and 23.7 ± 4.6 at last visit. Mean scores for the VAT were 7.7 ± 3.2 at baseline and 6.9 ± 3.6 at last visit respectively (Figure 2b), while CDT scores were on average 2.9 ± 1.3 at baseline and 3.3 ± 1.5 at last visit (Figure 2c). Detailed demographics, neuropsychological and neuropathological measurements at the individual level are listed in Supplementary Table S1.




Figure 2. Distribution of performance on selected neuropsychological tests within the group of centenarians at baseline and last visit.

For all neuropsychological tests, $n=40$. If a test was not administered or not completed, the score was indicated as not available (N/A), set apart from the scores by a dashed line. Dots are scattered to ensure visibility of all points. Cases for which only baseline data is available (T0) are shown as black circles, cases with one (T1), two (T2) or three (T3) follow-up visit are shown as blue squares and red or green triangles respectively.

Correlations between different neuropathological hallmarks

The levels of neuropathological hallmarks of AD are inter-correlated (Figure 3 and Supplementary Table S3). Particularly, Braak stage for NFTs correlated significantly with GVD levels (false discovery rate (fdr) = 0.002), and to a lesser extent with CERAD scores (fdr = 0.196). Thal stage for A β correlated significantly with levels of CAA and Braak stages (fdr = 0.8; and fdr = 0.16 respectively), and as expected with CERAD scores (fdr = 4.46^{E-16}). pTDP-43 stage is strongly correlated with hippocampal sclerosis (fdr = 0.044). In contrast, the levels of alpha-synuclein were not associated with the levels of any other assessed neuropathology.

Correlations between test performance, demographic characteristics and pathology

We observed an overall trend that performance correlates among cognitive tests. For the centenarians who completed cognitive tests at baseline and at last visit, we find a strong correlation between performances (Figure 3). The ability to complete testing was associated with lower ages at death, researcher impression of cognitive health and higher baseline MMSE scores. Likewise, we observed that pathology loads correlate among some pathology subtypes. We also observe an overall trend that lower pathology loads correlate with better performance on tests (Figure 3). This trend is mainly carried by the association of Braak stages for NFTs and higher GVD stages with lower cognitive performance across all tests. Higher Thal stages for A β pathology and higher CERAD scores also show this trend with lower test performance, but to a much lesser extent. Two specific associations stand out: First, increased loads of CAA correlated significantly with a low CDT performance at baseline (fdr = 0.156) and, despite a smaller group-size, this association was intensified for CDT performance at last visit (fdr = 0.02). Second, the presence and severity of hippocampal sclerosis correlated with a decreased ability to complete testing at follow up visits (fdr = 0.03) and non-significantly with a lower performance on the MMSE, both at baseline (fdr = 0.46), and last visit (fdr = 0.24). GVD stage only correlated with a low MMSE performance at baseline (fdr=0.16). This correlation was lost at last visit (fdr = 0.25).




Figure 3. Pearson correlation plot with false discovery rate (fdr). Color and size of the circles indicate the strength of the Pearson correlation coefficient (for Pearson correlation coefficient, p-value and numerical fdr see Supplementary Tables 3a-c), asterisks indicate the false discovery rate (*<20%, **<10%, ***<5%). Correlations between the same test at baseline and last visit were performed for 20 cases with at least one follow up visit. Thal stage GVD* indicates that we utilized a staging system for GVD adapted from Thal et al., 2011.

Case report of 103 year old female

One case was a female centenarian with a fit physique included in the 100-plus Study at the age of 102. She finished the first stage of tertiary education, and had enjoyed a total of 18 years of education (ISCED level 5). At baseline she scored 27 points on the MMSE and 3/5 points on the CDT. She volunteered to undergo an MRI and PIB-PET scan 1 month after inclusion into the study. The MRI scan revealed moderate hippocampal atrophy (MTA score 2), white matter abnormalities (Fazekas score II), and few microbleeds. The PET scan using [11C]

PiB as an amyloid tracer was positive throughout the brain, with the highest signal in the frontal area (Figure 4). The centenarian died 10 months after inclusion of cachexia. Proxies reported maintained cognitive health until the terminal phase. Brain autopsy was performed with a post mortem delay of 8.5 h. Overall, no major abnormalities were observed at the macroscopic level. Mild atrophy of the temporal lobe was observed and arteries were mildly atherosclerotic. Two small meningiomas were observed in the left part of the skull, as well as a small (0.6 cm) old cortical infarct in the medial frontal gyrus. The substantia nigra appeared relatively pale. Neuropathological evaluation revealed intermediate AD neuropathologic changes (A3B2C1). Consistent with the positive amyloid PET scan *in vivo*, we observed A β pathology in the form of classical and diffuse plaques (Thal stage A β 4), as well as capillary CAA-type 1 (capCAA) (Thal stage CAA 2) (Figure 5 panel d-f) during the post-mortem neuropathological analysis. Diffuse A β deposits were detected in the frontal, frontobasal, occipital, temporal and parietal cortex, the molecular layer, CA1 and subiculum of the hippocampus, as well as the caudate nucleus, putamen and nucleus accumbens. A relatively low number of classic senile plaques with a dense core was observed throughout the neocortex. Prominent presence of CAA was observed in the parietal cortex and the leptomeninges. Capillary CAA (type 1) was observed in moderate levels in the frontal cortex (Figure 5, panel f), the cerebellum, sporadically in the occipital cortex, and was absent in the temporal cortex. Together, the relatively high levels of CAA might explain the high signal of the [11C]PiB-PET, as CAA is also known to be detected by this tracer (Farid et al., 2017 [15]), as well as the abnormalities observed on the MRI. Immunostaining for pTau showed prominent occurrence of dystrophic neurites, neurofibrillary tangles and pretangles in the hippocampal areas CA1, subiculum and transentorhinal cortex. Moderate numbers of pretangles and threads were observed in the frontal cortex and occipital cortex. Severe presence of pTau immunoreactive neuropil threads and (pre)tangles was observed in the temporal cortex. Additionally, we observed pTau positive glial cells in the temporal cortex and subcortical white matter. In the anterior part of the hippocampus, pTau positive glial cells were observed associated with blood vessels, also indicative of ARTAG [24]. pTau positive neurons and glial cells were also observed in the amygdala and insula. In summary, immuno-positive pTau was observed as NFTs (Braak stage IV) and NP like structures (CERAD score 1), as well as in the form of ARTAG (Figure 5, panel g-i). GVD (CK1 δ positive granules) was present in high numbers in the hippocampal subfields CA1 and subiculum, CA4, entorhinal cortex, temporal cortex, amygdala and gyrus cinguli (Thal stage GVD* 5) (Figure 5, panel j-k). Accumulations of pTDP-43 pathology were widespread, including the amygdala, hippocampus and temporal pole cortex

(pTDP-43 stage 3) (Figure 5, panel a-c). No α -synuclein inclusions were observed in hippocampus, substantia nigra, amygdala, locus coeruleus, and in the nuclei of the medulla oblongata. A relative moderate decrease of Purkinje cells was observed in the cerebellum.




Figure 4. Dynamic $[^{11}\text{C}]\text{PiB}$ -PET and MRI scan for 11C-PIB of case 2015-060.

The scan was performed by the ECAT EXACT HR1 scanner (Siemens/CTI) one month after study inclusion. PET scan for amyloid is positive in the frontal area, MRI shows moderate hippocampal atrophy (MTA score 2) as well as vascular lesions in the white matter (Fazekas score II), suggesting amyloid angiopathy.




Figure 5. Representative neuropathological lesions found in the hippocampus (a,d,g,j), middle temporal lobe cortex (b,e,h,i,k), amygdala (c) and frontal lobe cortex (f) of case 2015-060. Shown are exemplary pTDP-43 accumulations (a-c) in the hippocampal subregion CA1 (a1) and dentate gyrus (DG) (a2), temporal pole cortex (T) (b) and Amygdala (Amy) (c), A β positivity (d-f) in the form of diffuse and classical plaques in the hippocampal CA1 region (d) and temporal pole cortex (e), as well as CAA of large vessels and capillaries in the frontal lobe (F2) (f). pTau immuno-staining (g-i) is shown as (pre)tauangles and neuritic plaque like structures in the hippocampal CA1 region (g) and temporal pole cortex (h1 and h2), as well as astroglial pTau in ARTAG in the temporal pole cortex (i1 and i2). GVD (CK1 δ granules) (j-k) is shown in the hippocampus (j) and temporal pole cortex (k). Scale bar 25 μ m.

DISCUSSION

In a unique cohort of 40 centenarians, in which individual cognitive functioning was assessed shortly before death, we investigated the post-mortem brain for disease- and aging-associated neuropathological changes. At baseline, cognitive performance varied: neuropsychological test performance suggested that some centenarians had no symptoms of cognitive impairment, while others showed considerable impairment in several cognitive domains. Furthermore, a small subset of centenarians with multiple follow-up visits showed some decline after study inclusion, while others remained cognitively stable until death. We also observed an overall trend that higher pathology loads associate amongst each other, but also with a lower performance on cognitive tests: this trend is carried especially by the NFT and GVD loads and to a lesser extent by A β -associated pathologies. Whereas previous findings indicated that many elderly individuals with CAA remain asymptomatic [15], our results suggested that the severity of amyloid accumulation in the vessel walls (CAA), but not A β accumulation in the form of plaques, significantly associated with lower executive functioning, as measured by the Clock Drawing Test (CDT).

To indicate the uniqueness of each centenarian and the importance of studying clinicopathological correlations in this special group we present a selected centenarian who appeared lively and healthy upon visiting our hospital with no signs of cognitive impairment, judged independently by a trained researcher and a neurologist. Both her hearing and visual abilities were good. While she scored 27 points on the MMSE, which is well above the age-groups cut-off score to indicate dementia [21], she did not attain maximum scores on the VAT (9/12) and the CDT (3/5). Scoring 3 points on the CDT indicates that while the visuospatial organization of the clock was correct, the centenarian had difficulties to place the hands of the clock correctly to 10 past 11. This might suggest some difficulties with visuo-spatial and/or executive functioning. She died 9 months later of cachexia. Despite her overall and cognitive well-being, a PiB-PET scan performed in the same week as the neuropsychological assessment was positive for amyloid A β , and we observed abnormalities in the MRI scan. During post-mortem neuropathological characterization, we found a prominent presence of diffuse A β deposits, relatively few classical and neuritic plaques, and a moderate level of CAA type 1, especially in the frontal lobe. Together, the relatively few diffuse A β deposits but relatively high levels of CAA might explain the high signal of the PiB-PET, as CAA is also known to be detected by this tracer [15]. The presented case was carrier of the ApoE2/4 genotype, which has been associated with a higher chance of developing AD relative to ApoE3/3 carriers [8], and possibly with an increased occurrence of CAA

[32]. Pre-mortem imaging is at present not able to replace thorough post-mortem characterization of pathology. The combination of both techniques and cognitive testing in the present case allows us to confirm pre-mortem scan observations post-mortem and to rule out that a considerable amount of the post-mortem observed pathology built up after the cognitive testing and brain scans. Together, our findings suggest that cognitive performance of self-reported cognitively healthy centenarians is, at least in part, sensitive to the increase of neuro- pathological hallmarks of disease, while individual cases manage to maintain high cognitive functioning in the presence of considerable amounts of multiple pathologies.

Accumulation of neuropathologies is common in centenarians

A β pathology was present in most centenarians at variable levels, and Braak stages for NFT were found in all centenarians. Distribution occurred up to stage IV, and we did not observe Braak stages 0, V or VI. Similarly, we detected significant accumulations of NPs, which did not exceed CERAD score 2. In fact, several centenarians have exceptionally good brain function with a high NFT load (Braak stage IV) and NP accumulations (CERAD scores 1 or 2), as well as high A β load (Thal stages 3–5). This is intriguing, since most younger individuals with similar amounts of pathology, namely Braak stage NFT III and IV, have at least some symptoms of AD [6, 31, 42]. An apparent dissociation of the association between Braak stage NFT and cognitive status at higher ages has also been reported previously [9, 31]. Overall, the cognitive function of these centenarians was conserved despite the presence of neuropathological hallmarks. We also find that several centenarians have no or only low amounts of A β pathology and intermediate levels of NFT loads, corresponding with the neuropathological description of primary age-related tauopathy (PART) [12]. The relation between PART and the occurrence of dementia is still elusive and its implications for cognition are still debated [14, 20]. The centenarians with PART in this cohort show variable performance on neuropsychological tests.

Thus far, many neuropathological changes such as ARTAG, atherosclerosis, hippocampal sclerosis, pTDP-43, GVD and Lewy bodies, are reported to accumulate with age independently of cognitive decline [1, 23, 24, 30, 42], while the simultaneous occurrence of multiple pathologies in elderly cases has previously been associated with increased dementia risk [22]. All centenarians presented high stages of GVD pathology, as well as atherosclerosis and ARTAG. GVD is known to accompany Tau pathology

[34] and its occurrence and distribution throughout the brain in AD has been first described in 2011[61]. To our knowledge, there are no reports regarding

GVD levels at extreme ages. Hunter and colleagues have described GVD in the hippocampal tissue of a cohort with the mean age of 90 and found associations of severe GVD with dementia status similar to that of severe NFTs [28]. In line with the findings by Hunter and colleagues, our findings illustrate that GVD is universal in extremely aged individuals and that in non-demented elderly, the associations of GVD with cognitive test performance is of similar strength as that observed with Braak stages [28]. In contrast, the accumulation of pTDP-43 is usually observed in cases with FTD or ALS, but has also been described to occur in AD patients and non-demented elderly [28, 29, 42, 51]. The occurrence in centenarians was limited and we observed no association with cognitive test performance. pTDP-43 aggregation has been suggested to be facilitated by A β pathology [42], for which we find only weak evidence in centenarians. We find that higher pTDP-43 stages occurred in all cases with hippocampal sclerosis, which is in agreement with previous observations [28]. Hippocampal sclerosis has previously been associated with lower performance on neuropsychological tests [30], and here we find a significant association with the inability to complete tests, a possible proxy for fatigue. Likewise, the accumulation of α -synuclein (Lewy bodies) was also limited in centenarians, despite the reported increased occurrence of this pathology with age [42]. We did not observe a correlation between the presence of Lewy bodies and cognitive function. The overall low occurrence of pTDP-43 and Lewy body pathologies in this group of centenarians implies that these pathologies are more likely disease-related and not aging-related. In addition, we found one odd case with a Braak stage 6 for Lewy bodies, who was diagnosed with Parkinson's disease many years before death, but performed well on the MMSE. The occurrence of strokes and other vascular pathologies has been shown to be a major risk factor of dementia in individuals over 85 [10]. However, brain infarcts of any size have not shown good correlation to cognitive test performance in the current sample. We found very weak negative association of occurrence of infarcts with lower MMSE scores at last visit and CDT at baseline.

In our cohort of centenarians, increased levels of pathology correlate with lower cognitive performance. Apart from the strong association of CAA severity with performance on the CDT, Thal stage GVD* specifically associates with lower performance on the MMSE, and hippocampal sclerosis is associated with the ability to complete testing. The two pathological hallmarks that associate with most cognitive measures are Thal stage GVD* and the Braak stage NFT, although most associations are weak, suggesting that the presence of one or two neuropathological hallmarks is not sufficient to evoke cognitive symptoms. This observation is in agreement with the idea that the simultaneous accumulation of different neuropathological hallmarks of AD could collectively account for the

cognitive decline that is associated with aging [20–22, 31, 42]. It should however be kept in mind that the present study does not include any cases with clinically overt dementia and that the reported associations between pathological hallmarks and cognitive test performance describe very subtle changes in cognition. It remains elusive whether these centenarians retained their cognitive health to extreme ages because they delayed the accumulation of pathologies to much later ages, or because build-up of pathology was slower. Additionally, cognitively healthy centenarians might possess compensatory mechanisms, e.g. to maintain synapse numbers and health, as synaptic loss has previously been implicated as the main driver of cognitive impairment [37]. More in-depth molecular analysis, such as quantitative immunohistochemical analysis and proteomic characterization, will be necessary to gain new insights into the molecular changes and possible compensatory mechanisms underlying cognitive decline or maintained cognitive health at old age.

Thus far, we present the findings in a sample of 40 centenarians. With the continuation of this prospective study, we will be able to validate these findings in a larger sample in due time. Also, as of yet we did not observe a cognitively healthy centenarian who was free of atherosclerosis or AD-associated pathologies, as reported previously for a 115 year old woman [13]. In line with reports that cognitive performance is highly correlated with survival in the oldest old [41], we find that the centenarians who score highest on cognitive tests in the ongoing prospective study are underrepresented among the first centenarians in the 100-plus Study who came to autopsy (data not shown). We therefore speculate that individuals with a low burden of pathology might survive until extreme ages, and will come to autopsy at a later time after inclusion.

Conclusions

In conclusion, we find that AD associated neuropathology is common in centenarians, albeit within limits for specific neuropathological hallmarks. Furthermore, we find that although the centenarians in this cohort escaped or delayed cognitive impairment until extreme ages, the accumulation of overall pathologies relate with lower cognitive performance. It remains unclear whether pathology accumulation was slower compared to others, or whether accumulation started later. Overall, the registration of ante-mortem cognitive performance combined with thorough post-mortem brain analysis provides a unique window of opportunity for the association of cognitive function with the occurrence of neuropathological changes in centenarians.

ACKNOWLEDGEMENTS

We thank and acknowledge all participating centenarians and their family members and the persons who contributed to this work as part of their bachelors' and masters' thesis: Neline van Woerden, Elleke Tissink, Melissa de Reus, Rianne Koeling, Ramon Bettings and Julia Letschert.

COMPETING INTERESTS

The authors declare that they have no competing interest.

REFERENCES

1. Alafuzoff I, Gelpi E, Al-Sarraj S, Arzberger T, Attems J, Bodi I, Bogdanovic N, Budka H, Bugiani O, Englund E, Ferrer I, Gentleman S, Giaccone G, Graeber MB, Hortobagyi T, Höftberger R, Ironside JW, Jellinger K, Kavantzias N, King A, Korkolopoulou P, Kovács GG, Meyronet D, Monoranu C, Parchi P, Patsouris E, Roggendorf W, Rozemuller A, Seilhean D, Streichenberger N, Thal DR, Wharton SB, Kretschmar H (2012) The need to unify neuropathological assessments of vascular alterations in the ageing brain. Multicentre survey by the BrainNet Europe consortium. *Exp Gerontol* 47: 825–833. <https://doi.org/10.1016/j.exger.2012.06.001>
2. Alafuzoff I, Ince PG, Arzberger T, Al-Sarraj S, Bell J, Bodi I, Bogdanovic N, Bugiani O, Ferrer I, Gelpi E, Gentleman S, Giaccone G, Ironside JW, Kavantzias N, King A, Korkolopoulou P, Kovács GG, Meyronet D, Monoranu C, Parchi P, Parkkinen L, Patsouris E, Roggendorf W, Rozemuller A, Stadelmann-Nessler C, Streichenberger N, Thal DR, Kretschmar H (2009) Staging/typing of Lewy body related α -synuclein pathology: a study of the BrainNet Europe consortium. *Acta Neuropathol* 117:635–652. <https://doi.org/10.1007/s00401-009-0523-2>
3. Braak H, Alafuzoff I, Arzberger T, Kretschmar H, Tredici K (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. *Acta Neuropathol* 112:389–404. <https://doi.org/10.1007/s00401-006-0127-z>
4. Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol* 82:239–259. <https://doi.org/10.1007/BF00308809>
5. Braak H, Braak E (1995) Staging of Alzheimer's disease-related neurofibrillary changes. *Neurobiol Aging* 16:271–278. [https://doi.org/10.1016/0197-4580\(95\)00021-6](https://doi.org/10.1016/0197-4580(95)00021-6)
6. Braak H, Braak E (1997) Frequency of stages of Alzheimer-related lesions in different age categories. *Neurobiol Aging* 18:351–357. [https://doi.org/10.1016/S0197-4580\(97\)00056-0](https://doi.org/10.1016/S0197-4580(97)00056-0)
7. Braak H, Del Tredici K, Rüb U, Vos RAI De, Jansen Steur ENH, Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol Aging* 24:197–211

8. Corneveaux JJ, Myers AJ, Allen AN, Pruzin JJ, Ramirez M, Engel A, Nalls MA, Chen K, Lee W, Chewning K, Villa SE, Meechoovet HB, Gerber JD, Frost D, Benson HL, O'Reilly S, Chibnik LB, Shulman JM, Singleton AB, Craig DW, Van Keuren-Jensen KR, Dunckley T, Bennett DA, de Jager PL, Heward C, Hardy J, Reiman EM, Huentelman MJ (2010) Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. *Hum Mol Genet* 19:3295–3301. <https://doi.org/10.1093/hmg/ddq221>
9. Corrada MM, Berlau DJ, Kawas CH (2012) A population-based clinicopathological study in the oldest-old: the 90+ study. *Curr Alzheimer Res* 9:709–717 doi: CAR-EPUB-20120402-004
10. Corrada MM, Mozaffar F, Evans MA, Bullain SS, Brookmeyer R, Kawas CH (2016) History of vascular disease and risk of dementia in the oldest-old: the 90+ study. *Alzheimers Dement* 12:P249–P250. <https://doi.org/10.1016/j.jalz.2016.06.447>
11. Corrada MM, Brookmeyer R, Paganini-Hill A, Berlau D, Kawas CH (2010) Dementia Incidence Continues to Increase with Age in the Oldest Old The 90+ Study. 67:114–121. <https://doi.org/10.1002/ana.21915>.Dementia
12. Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I, Arnold SE, Attems J, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Gearing M, Grinberg LT, Hof PR, Hyman BT, Jellinger K, Jicha GA, Kovacs GG, Knopman DS, Kofler J, Kukull WA, Mackenzie IR, Masliah E, McKee A, Montine TJ, Murray ME, Neltner JH, Santa-Maria I, Seeley WW, Serrano-Pozo A, Shelanski ML, Stein T, Takao M, Thal DR, Toledo JB, Troncoso JC, Vonsattel JP, White CL, Wisniewski T, Woltjer RL, Yamada M, Nelson PT (2014) Primary age-related tauopathy (PART): a common pathology associated with human aging. *Acta Neuropathol* 128:755–766. <https://doi.org/10.1007/s00401-014-1349-0>
13. den Dunnen WFA, Brouwer WH, Bijlard E, Kamphuis J, van Linschoten K, Eggens-Meijer E, Holstege G (2008) No disease in the brain of a 115-year-old woman. *Neurobiol Aging* 29:1127–1132. <https://doi.org/10.1016/j.neurobiolaging.2008.04.010>
14. Duyckaerts C, Braak H, Brion J, Buée L, Del Tredici K, Goedert M, Halliday G, Neumann M, Spillantini MG, Tolnay M, Uchihara T (2015) PART is part of Alzheimer disease. *Acta Neuropathol* 129:749–756. <https://doi.org/10.1007/s00401-015-1390-7>

17. Farid K, Charidimou A, Baron JC (2017) Amyloid positron emission tomography in sporadic cerebral amyloid angiopathy: a systematic critical update. *NeuroImage Clin* 15:247–263. <https://doi.org/10.1016/j.nicl.2017.05.002>
18. Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* 12:189–198. [https://doi.org/10.1016/0022-3956\(75\)90026-6](https://doi.org/10.1016/0022-3956(75)90026-6)
19. Gardner RC, Valcour V, Yaffe K (2013) Dementia in the oldest old: a multi-factorial and growing public health issue. *Alzheimers Res Ther* 5:27. <https://doi.org/10.1186/alzrt181>
20. Haroutunian V, Schnaider-Beerli M, Schmeidler J, Wysocki M, Purohit DP, Perl DP, Libow LS, Lesser GT, Maroukian M, Grossman HT (2008) Role of the neuropathology of Alzheimer disease in dementia in the oldest-old. *Arch Neurol* 65:1211–1217. <https://doi.org/10.1001/archneur.65.9.1211>
21. Holstege H, Beker N, Dijkstra T, Pieterse K, Wemmenhove E, Schouten K, van Poppel FWA, Meijers-Heijboer H, Hulsman M, Scheltens P (2018) The 100- plus study of Dutch cognitively healthy centenarians: rationale, design and cohort description. *BioRxiv* doi: <https://doi.org/10.1101/295287>
22. Jellinger KA, Attems J (2015) Challenges of multimorbidity of the aging brain : a critical update. *J Neural Transm*:505–521. <https://doi.org/10.1007/s00702-014-1288-x>
23. Kapasi A, DeCarli C, Schneider JA (2017) Impact of multiple pathologies on the threshold for clinically overt dementia. *Acta Neuropathol* 134:1–16. <https://doi.org/10.1007/s00401-017-1717-7>
24. Kawas CH, Kim RC, Sonnen JA, Bullain SS, Trieu T, Corrada MM (2015) Multiple pathologies are common and related to dementia in the oldest- old: the 90+ study. *Neurology* 85:535–542. <https://doi.org/10.1212/wnl.0000000000001831>
25. Köhler C (2016) Granulovacuolar degeneration: a neurodegenerative change that accompanies tau pathology. *Acta Neuropathol* 132:339–359. <https://doi.org/10.1007/s00401-016-1562-0>

26. Kovacs GG, Ferrer I, Grinberg LT, Alafuzoff I, Attems J, Budka H, Cairns NJ, Crary JF, Duyckaerts C, Ghetti B, Halliday GM, Ironside JW, Love S, Mackenzie IR, Munoz DG, Murray ME, Nelson PT, Takahashi H, Trojanowski JQ, Ansorge O, Arzberger T, Baborie A, Beach TG, Bieniek KF, Bigio EH, Bodi I, Dugger BN, Feany M, Gelpi E, Gentleman SM, Giaccone G, Hatanpaa KJ, Heale R, Hof PR, Hofer M, Hortobágyi T, Jellinger K, Jicha GA, Ince P, Kofler J, Kövari E, Kril JJ, Mann DM, Matej R, McKee AC, McLean C, Milenkovic I, Montine TJ, Murayama S, Lee EB, Rahimi J, Rodriguez RD, Rozemüller A, Schneider JA, Schultz C, Seeley W, Seilhean D, Smith C, Tagliavini F, Takao M, Thal DR, Toledo JB, Tolnay M, Troncoso JC, Vinters HV, Weis S, Wharton SB, White CL, Wisniewski T, Woulfe JM, Yamada M, Dickson DW (2016) Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. *Acta Neuropathol* 131:87–102. <https://doi.org/10.1007/s00401-015-1509-x>
27. Lindeboom J, Schmand B, Tulner L, Walstra G (2002) Visual association test to detect early dementia of the Alzheimer type. *J Neurol Neurosurg Psychiatry* 73:126–133. <https://doi.org/10.1136/jnnp.73.2.126>
28. Mirra S, Heyman A, McKeel D, Sumi S, Crain B, Brownlee L, Vogel F, Hughes J, van Belle G, Berg L (1991) The consortium to establish a registry for Alzheimer's disease (CERAD). Part II Stand Neuropathologic Assessment Alzheimer's Dis 41:479–486
29. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV, Hyman BT (2012) National institute on aging-Alzheimer's association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. *Acta Neuropathol* 123:1–11. <https://doi.org/10.1007/s00401-011-0910-3>
30. Nag S, Yu L, Capuano AW, Wilson RS, Leurgans SE, Bennett DA,
31. Schneider JA (2015) Hippocampal sclerosis and TDP-43 pathology in
32. aging and Alzheimer disease. *Ann Neurol* 77:942–952. <https://doi.org/10.1002/ana.24388>
33. Nag S, Yu L, Wilson RS, Chen EY, Bennett DA, Schneider JA (2017) TDP-43 pathology and memory impairment in elders without pathologic diagnoses of AD or FTL. *Neurology* 88:653–660. <https://doi.org/10.1212/WNL.0000000000003610>

34. Nelson PT, Schmitt FA, Lin Y, Abner EL, Jicha GA, Patel E, Thomason PC, Neltner JH, Smith CD, Santacruz KS, Sonnen JA, Poon LW, Gearing M, Green RC, Woodard JL, Van Eldik LJ, Kryscio RJ (2011) Hippocampal sclerosis in advanced age: clinical and pathological features. *Brain* 134:1506–1518. <https://doi.org/10.1093/brain/awr053>
35. Nelson P. T. et al (2012) Correlation of alzheimer disease neuropathologic changes with cognitive status: a review of the literature. *J Neuropathol Exp Neurol* 2012 May; 71(5) 362–381 <https://doi.org/10.1097/NEN.0b013e31825018f7>.Correlation
36. Neltner JH, Abner EL, Jicha GA, Schmitt FA, Patel E, Poon LW, Marla G, Green RC, Davey A, Johnson MA, Jazwinski SM, Kim S, Davis D, Woodard JL, Kryscio RJ, Van Eldik LJ, Nelson PT (2015) Brain pathologies in extreme old age. *Neurobiol Aging*. <https://doi.org/10.1016/j.neurobiolaging.2015.10.009>
37. NIA (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan institute working group on diagnostic criteria for the Neuropathological assessment of Alzheimer's disease. *Neurobiol Aging* 18:S1–S2. [https://doi.org/10.1016/S0197-4580\(97\)00057-2](https://doi.org/10.1016/S0197-4580(97)00057-2)
38. Pascual G, Wadia JS, Zhu X, Keogh E, Kükreer B, van Ameijde J, Inganäs H, Siregar B, Perdok G, Diefenbach O, Nahar T, Sprengers I, Koldijk MH, van d LECB, Peferoen LA, Zhang H, Yu W, Li X, Wagner M, Moreno V, Kim J, Costa M, West K, Fulton Z, Chammas L, Luckashenak N, Fletcher L, Holland T, Arnold C, Anthony Williamson R, Hoozemans JJ, Apetri A, Bard F, Wilson IA, Koudstaal W, Goudsmit J (2017) Immunological memory to hyperphosphorylated tau in asymptomatic individuals. *Acta Neuropathol* 133:767–783. <https://doi.org/10.1007/s00401-017-1705-y>
39. Prince M, Wimo A, Guerchet M, Gemma-Claire A, Wu Y-T, Prina M (2015) World Alzheimer report 2015: the global impact of dementia - an analysis of prevalence, incidence, cost and trends. *Alzheimer's Dis Int* 84. <https://doi.org/10.1111/j.0963-7214.2004.00293.x>
40. R Core Team, R Foundation for Statistical Computing, Vienna A (2016) R: A Language and Environment for Statistical Computing
41. Robinson JL, Molina-Porcel L, Corrada MM, Raible K, Lee EB, Lee VMY, Kawas CH, Trojanowski JQ (2014) Perforant path synaptic loss correlates with cognitive impairment and Alzheimer's disease in the oldest-old. *Brain* 137: 2578–2587. <https://doi.org/10.1093/brain/awu190>

42. Savva GM, Wharton SB, Ince PG (2009) Age, neuropathology, and dementia — NEJM. *N Engl J Med* 361:1118. <https://doi.org/10.1056/NEJMoA0806142>
43. Shulman KI (2000) Clock drawing: is it the ideal cognitive screening test? *Int J Geriatr Psychiatry* 15:548–561. [https://doi.org/10.1002/1099-1166\(200006\)15:6<548::AID-GPS242>3.0.CO;2-U](https://doi.org/10.1002/1099-1166(200006)15:6<548::AID-GPS242>3.0.CO;2-U)
44. Shulman KI, Pushkar Gold D, Cohen CA, Zuccherro CA (1993) Clock-drawing and dementia in the community: a longitudinal study. *Int J Geriatr Psychiatry* 8:487–496. <https://doi.org/10.1002/gps.930080606>
45. Skoog J, Backman K, Ribbe M, Falk H, Gudmundsson P, Thorvaldsson V, Borjesson-Hanson A, Ostling S, Johansson B, Skoog I (2017) A longitudinal study of the mini-mental state examination in late nonagenarians and its relationship with dementia, mortality, and education. *J Am Geriatr Soc* 65: 1296–1300. <https://doi.org/10.1111/jgs.14871>
46. Spires-Jones TL, Attems J, Thal DR (2017) Interactions of pathological proteins in neurodegenerative diseases. *Acta Neuropathol* 134:1–19. <https://doi.org/10.1007/s00401-017-1709-7>
47. Takao M, Hirose N, Arai Y, Mihara B, Mimura M (2016) Neuropathology of supercentenarians - four autopsy case studies. *Acta Neuropathol Commun* 4:97. <https://doi.org/10.1186/s40478-016-0368-6>
48. Thal DR, Del Tredici K, Ludolph AC, Hoozemans JJM, Rozemuller AJ, Braak H, Knippschild U (2011) Stages of granulovacuolar degeneration: their relation to Alzheimer's disease and chronic stress response. *Acta Neuropathol* 122: 577–589. <https://doi.org/10.1007/s00401-011-0871-6>
49. Thal DR, Ghebremedhin E, Rüb U, Yamaguchi H, Del Tredici K, Braak H (2002) Two types of sporadic cerebral amyloid angiopathy. *J Neuropathol Exp Neurol* 61:282–293. <https://doi.org/10.1093/jnen/61.3.282>
50. Thal DR, Rüb U, Orantes M, Braak H (2002) Phases of a beta-deposition in the human brain and its relevance for the development of AD. *Neurology* 58:1791–1800. <https://doi.org/10.1212/WNL.58.12.1791>
51. Thal DR, Rüb U, Schultz C, Sassin I, Ghebremedhin E, Del Tredici K, Braak E, Braak H (2000) Sequence of Aβ_{25–35}-protein deposition in the human medial temporal lobe. *J Neuropathol Exp Neurol* 59:733–748
52. Uchihara T (2007) Silver diagnosis in neuropathology: principles, practice and revised interpretation. *Acta Neuropathol* 113:483–499. <https://doi.org/10.1007/s00401-007-0200-2>
53. UNESCO. International Standard Classification of Education ISCED 1997 http://www.unesco.org/education/information/nfsunesco/doc/isced_1997.htm

54. Verwey NA, Hoozemans JJM, Korth C, van Royen MR, Prikulis I, Wouters D, Twaalfhoven HAM, van Haastert ES, Schenk D, Scheltens P, AJM R, Blankenstein MA, Veerhuis R (2013) Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid β -peptide. *Amyloid* 20:179–187. <https://doi.org/10.3109/13506129.2013.797389>
55. Wilson RS, Yu L, Trojanowski JQ, Chen E-Y, Boyle PA, Bennett DA, Schneider JA (2013) TDP-43 pathology, cognitive decline, and dementia in old age. *JAMA Neurol* 70:1418. <https://doi.org/10.1001/jamaneurol.2013.3961>

APPENDIX

Supplementary Table S1. Overview of all variables used in correlation plot in Figure 3

| Variable | Scoring | Reference |
|-----------------------------|---|---|
| Sex | Female 0, Male 1 | |
| Education, [y] | Years of formal education (low-high) | |
| <i>APOE</i> OR | ranked according to their association with increased AD-risk OR's E2/2 (OR 0.24); E2/3 (OR 0.5); E3/3 (OR 1.0); E2/4 (OR 3.2); E3/4 (OR 5.5) | Corneveaux et al., 2010 [8] |
| Age at death, [y] | 100 - 110.29 | |
| MMSE score | 0-30 (bad-good) | Folstein et al., 1975 [16] |
| VAT score, trial 1+2 | 0-12 (bad-good) | Lindeboom et al., 2002 [25] |
| CDT score | 0-5 (bad-good) | Shulman et al., 1993, 2000 [39, 40] |
| Ability to complete testing | Good to bad 0 no tests completed 1 MMSE was completed, but not VAT and/or CDT 2 all tests completed or tests not applied due to sensory problems | |
| Cognitive health impression | 0 symptoms of impairment 1 possible symptoms of impairment 2 no symptoms of impairment | |
| Brain weight | Shown in grams | |
| Atrophy | 0-3 (absent-severe) absent (0) mild (1) moderate (2) severe (3) | |
| Braak stage for Lewy bodies | 0-VI (absent-severe) | Braak et al., 2003 [7] |
| Atherosclerosis | 0-3 (absent-severe) absent (0) mild (1) moderate (2) severe (3) | In correspondence with the Netherlands Brain Bank |
| Thal stage CAA | 0-3 (absent-severe) | Thal et al., 2002 [45] |
| Thal stage A β | 0-5 (absent-severe) | Thal et al., 2002 [46] |
| CERAD score | 0-3 (absent-severe) | Mirra et al., 1991 [26] |

Supplementary Table S1. Overview of all variables used in correlation plot in Figure 3 (continued)

| Variable | Scoring | Reference |
|-----------------------|---|---------------------------------|
| Braak stage | 0-VI (absent-severe) | Braak and Braak, 1991 [4] |
| Thal stage GVD* | 0-5 (absent-severe) | Based on Thal et al., 2011 [44] |
| Infarcts | absent (1) or present (2) | Nag et al., 2015 [28] |
| pTDP-43 stage | 0-3 (absent-severe) | |
| Hippocampal sclerosis | no hippocampal sclerosis (0) unilateral hippocampal sclerosis (1) bilateral hippocampal sclerosis (2) | |

OR=Odd's ratio's. MMSE=Mini-Mental State Examination. APOE=Apolipoprotein. VAT=Visual Association Test. CDT=Clock drawing test. CAA=Cerebral amyloid angiopathy. GVD=Granulovacuolar degeneration. ARTAG=Aging-related tau astrogliopathy. CERAD=Consortium to establish a registry for Alzheimer's disease.

Supplementary Table S2. Subject demographics and overview of neuropathological hallmarks of centenarians

| No. | Sex | No. of visits | Bas. age [y] | Bas. MMSE score | Bas. VAT score | Bas. CDT score | Age [y] at last visit | MMSE score at last visit | VAT score at last visit | CDT score at last visit | Ability to complete testing | Cognitive health impr. | Age at death [y] | Educ. level | Educ. [y] | post-mortem delay [h:m] | APOE allele |
|-----|-----|---------------|--------------|-----------------|----------------|----------------|-----------------------|--------------------------|-------------------------|-------------------------|-----------------------------|------------------------|------------------|-------------|-----------|-------------------------|-------------|
| 1 | f | 1 | 100.9 | 30 | NA | 5 | 100.9 | 30 | NA | 5 | 2 | 2 | 101.7 | 5 | 15 | 06:15 | E3/E3 |
| 2 | f | 1 | 100.3 | 22 | NA | 1 | 100.3 | 22 | NA | 1 | 2 | 2 | 101.6 | 5 | 13 | 07:27 | E3/E4 |
| 3 | f | 1 | 110.3 | NA | NA | NA | 110.3 | NA | NA | NA | 0 | 2 | 111.8 | 1 | 6 | 08:40 | E2/E3 |
| 4 | m | 1 | 102.5 | 9 | NA | NA | 102.5 | 9 | NA | NA | 1 | 1 | 102.9 | 3 | 10 | 05:26 | E3/E3 |
| 5 | m | 1 | 102.5 | 22 | 11 | NA | 102.5 | 22 | 11 | NA | 2 | 2 | 102.7 | 4 | 12 | 10:00 | E2/E3 |
| 6 | m | 1 | 102.7 | 19 | NA | 2 | 102.7 | 19 | NA | 2 | 1 | 2 | 103.9 | 3 | 10 | 05:05 | E3/E3 |
| 7 | f | 1 | 103.0 | 27 | 9 | 3 | 103.0 | 27 | 9 | 3 | 2 | 2 | 103.8 | 5 | 18 | 08:24 | E2/E4 |
| 8 | f | 2 | 101.1 | 24 | NA | 2 | 103.0 | 23 | NA | NA | 2 | 2 | 103.8 | 1 | 6 | 07:55 | E3/E3 |
| 9 | f | 2 | 103.2 | 15 | 0 | NA | 104.2 | NA | NA | NA | 0 | 1 | 104.3 | 6 | 19 | 04:15 | E3/E3 |
| 10 | m | 1 | 102.0 | 23 | 7 | 1 | 102.0 | 23 | 7 | 1 | 2 | 2 | 103.0 | 4 | 9 | 07:45 | E3/E3 |
| 11 | f | 1 | 101.6 | 21 | 5 | 5 | 101.6 | 21 | 5 | 5 | 2 | 2 | 102.1 | 2 | 6 | 06:10 | E2/E3 |
| 12 | f | 2 | 100.3 | 25 | 7 | 3 | 101.2 | 25 | NA | 4 | 1 | 2 | 102.0 | 1 | 6 | 07:55 | E3/E3 |
| 13 | m | 1 | 100.3 | 25 | 10 | 3 | 100.3 | 25 | 10 | 3 | 2 | 2 | 101.2 | 5 | 18 | 05:30 | E3/E4 |
| 14 | m | 2 | 105.7 | 25 | 8 | 3 | 106.5 | NA | NA | NA | 0 | NA | 107.2 | 4 | 9 | 05:30 | E3/E3 |
| 15 | f | 2 | 100.9 | 29 | NA | NA | 101.9 | 26 | NA | NA | 2 | 2 | 102.6 | 4 | 10 | 05:17 | E3/E3 |
| 16 | f | 1 | 101.4 | 25 | 11 | 5 | 101.4 | 25 | 11 | 5 | 2 | 2 | 103.2 | 2 | 7 | 05:55 | E2/E3 |
| 17 | f | 3 | 101.9 | 27 | 5 | 2 | 104.2 | 27 | NA | NA | 2 | 2 | 104.8 | 5 | 15 | 07:55 | E3/E3 |
| 18 | f | 3 | 101.3 | 26 | 7 | 3 | 103.3 | 25 | 5 | 5 | 2 | 2 | 103.5 | 2 | 8 | 04:00 | E3/E3 |
| 19 | f | 3 | 99.0 | 30 | 11 | 3 | 101.1 | 30 | 12 | 3 | 2 | 2 | 101.5 | 5 | 15 | 03:25 | E3/E3 |
| 20 | m | 1 | 100.8 | 26 | 11 | NA | 100.8 | 26 | 11 | NA | 2 | 2 | 102.8 | 1 | 7 | 04:05 | E3/E3 |
| 21 | f | 1 | 100.2 | 25 | 10 | 2 | 100.2 | 25 | 10 | 2 | 2 | NA | 100.9 | 1 | 6 | 08:40 | E3/E3 |
| 22 | f | 1 | 103.1 | 26 | 5 | 5 | 103.1 | 26 | 5 | 5 | 2 | 2 | 104.6 | 6 | 20 | 12:00 | E3/E3 |

Supplementary Table S2. Subject demographics and overview of neuropathological hallmarks of centenarians (*continued*)

| No. | Sex | No. of visits | Bas. age [y] | Bas. MMSE score | Bas. VAT score | Bas. CDT score | Age [y] at last visit | MMSE score at last visit | VAT score at last visit | CDT score at last visit | Ability to complete testing | Cognitive health impr. | Age [y] at death | Educ. level | Educ. [y] | post-mortem delay [hm] | APOE allele |
|-----|-----|---------------|--------------|-----------------|----------------|----------------|-----------------------|--------------------------|-------------------------|-------------------------|-----------------------------|------------------------|------------------|-------------|-----------|------------------------|-------------|
| 23 | f | 2 | 103.3 | 26 | NA | 2 | 104.3 | 26 | 0 | NA | 2 | 1 | 104.9 | 1 | 6 | 04:10 | E2/E3 |
| 24 | f | 2 | 100.2 | 24 | 12 | NA | 101.2 | 16 | 8 | NA | 2 | 1 | 101.4 | 1 | 6 | 06:40 | E3/E3 |
| 25 | f | 1 | 100.2 | 15 | NA | NA | 100.2 | 15 | NA | NA | 2 | 1 | 100.4 | 1 | 6 | 05:00 | NA |
| 26 | f | 1 | 107.3 | 26 | 4 | NA | 107.3 | 26 | 4 | NA | 2 | 2 | 108.4 | 1 | 6 | 06:10 | E3/E3 |
| 27 | f | 3 | 98.3 | 27 | 9 | 4 | 101.0 | 30 | 2 | 4 | 2 | 2 | 102.0 | 4 | NA | 08:30 | E3/E3 |
| 28 | f | 2 | 102.1 | 26 | 8 | NA | 103.2 | 26 | NA | 3 | 2 | 2 | 104.1 | 1 | 7 | 10:30 | E3/E3 |
| 29 | m | 2 | 101.2 | NA | NA | NA | 103.0 | NA | NA | NA | 0 | NA | 105.2 | 2 | 9 | 06:05 | E3/E3 |
| 30 | f | 1 | 103.0 | 19 | 3 | 2 | 103.0 | 19 | 3 | 2 | 2 | 1 | 103.8 | 4 | 12 | 07:20 | E3/E3 |
| 31 | f | 1 | 101.5 | 23 | 5 | 3 | 101.5 | 23 | 5 | 3 | 2 | 2 | 102.4 | 2 | 8 | 05:50 | E3/E3 |
| 32 | f | 2 | 101.2 | 17 | 8 | 2 | 102.2 | NA | NA | NA | 0 | 0 | 102.4 | 1 | 6 | 10:45 | E3/E3 |
| 33 | m | 3 | 100.3 | 25 | 7 | 1 | 102.4 | 15 | 4 | NA | 2 | 1 | 102.6 | 3 | 8 | 06:40 | E2/E3 |
| 34 | f | 1 | 100.2 | 29 | NA | NA | 100.2 | 29 | NA | NA | 2 | 2 | 101.9 | 4 | 15 | 06:30 | E3/E3 |
| 35 | m | 3 | 100.4 | 26 | NA | NA | 102.3 | 23 | 7 | NA | 2 | 2 | 103.2 | 1 | 7 | 05:30 | E3/E3 |
| 36 | f | 2 | 100.3 | 24 | 11 | 3 | 101.3 | 26 | 10 | 5 | 2 | 2 | 102.1 | 1 | 7 | 05:47 | E3/E4 |
| 37 | f | 3 | 102.1 | 29 | NA | NA | 104.2 | 28 | NA | NA | 2 | 2 | 104.7 | 4 | 10 | 07:05 | E2/E4 |
| 38 | m | 2 | 101.3 | 28 | 11 | 3 | 102.3 | 22 | 5 | 3 | 2 | 2 | 103.1 | 3 | 8 | 05:05 | E3/E3 |
| 39 | f | 1 | 100.3 | 24 | 2 | 1 | 100.3 | 24 | 2 | 1 | 2 | 2 | 102.3 | 3 | 12 | 08:15 | E3/E3 |
| 40 | f | 4 | 103.8 | 28 | 11 | 5 | 106.8 | 26 | 12 | 5 | 2 | 2 | 107.1 | 3 | 8 | 05:40 | E3/E3 |

No.=Number. Bas.=Baseline. MMSE=Mini-Mental State Examination. VAT=Visual Association Test. CDT=Clock drawing test. Educ=Education. ISCED=International Standard Classification of Education. APOE=Apolipoprotein.

Supplementary Table S2. Continued

| Brain weight | No. [g] | Braak | | | AD neuro- | | | Thal | | | Braak | | | ARTAG | | |
|--------------|---------|---------|-----------|-------|-----------|---------------|--------------------------|---|-------------------------------------|-----------------|-----------------|------------------------|-------------------------|-----------------------|------------------------|-----------------|
| | | Atrophy | A β | stage | Thal | Braak & Braak | Neuritic plaques (CERAD) | AD neuro-pathologic change (NIA-Reagan) | AD neuro-pathologic change (NIA-AA) | stage CAA (0-3) | stage GVD (0-5) | Athero-sclerosis (0-3) | stage Lewy bodies (0-6) | TDP-43 stage AD (0-3) | Hippo-campal sclerosis | infarcts |
| 1 | 1155 | 0 | 3 | 3 | 0 | 0 | 0 | A2B2C0 | Intern. | 0 | 4 | 3 | 0 | 3 | no | yes |
| 2 | 1150 | 1 | 4 | 4 | 1 | 1 | 1 | A3B2C1 | Intern. | 2 | 5 | 1 | 0 | 0 | no | Cer |
| 3 | 972 | 1 | 4 | 3 | 2 | 2 | 2 | A3B2C2 | Intern. | 1 | 5 | 2 | 1 | 2 | yes, left CA1 | Par |
| 4 | 1130 | 1 | 3 | 4 | 2 | 2 | 2 | A2B2C2 | Intern. | 1 | 5 | 1 | 0 | 3 | yes, bilateral | Cer |
| 5 | 1230 | 1 | 0 | 3 | 0 | 0 | 0 | A0B2C0 | Not | 0 | 4 | 3 | 0 | 1 | no | no |
| 6 | 1195 | 0 | 3 | 2 | 1 | 1 | 1 | A2B1C1 | Low | 1 | 5 | 2 | 1 | 2 | yes, left | no |
| 7 | 1063 | 1 | 4 | 4 | 1 | 1 | 1 | A3B2C1 | Intern. | 2 | 5 | 1 | 0 | 3 | no | F2 |
| 8 | 1065 | 0 | 1 | 2 | 0 | 0 | 0 | A1B1C0 | Low | 0 | 4 | 3 | 0 | 0 | NA | Caud. |
| 9 | 1180 | 0 | 5 | 4 | 2 | 2 | 2 | A3B2C2 | Intern. | 1 | 5 | 1 | 0 | 3 | no | no |
| 10 | 1120 | 1.5 | 4 | 4 | 2 | 2 | 2 | A3B2C2 | Intern. | 2 | 5 | 2 | 0 | 2 | no | Occ |
| 11 | 1005 | 1 | 1 | 2 | 0 | 0 | 0 | A1B1C0 | Low | 0 | 4 | 2 | 0 | 0 | no | Thal |
| 12 | 1165 | 0 | 1 | 3 | 0 | 0 | 0 | A1B2C0 | Low | 1 | 4 | 1 | 0 | 0 | no | F |
| 13 | 1125 | 1 | 1 | 3 | 0 | 0 | 0 | A1B2C0 | Low | 1 | 4 | 1 | 0 | 0 | no | no |
| 14 | 1330 | 0 | 5 | 3 | 1 | 1 | 1 | A3B2C1 | Intern. | 1 | 5 | 2 | 0 | 3 | yes, bilateral | yes |
| 15 | 1026 | 1 | 4 | 3 | 1 | 1 | 1 | A3B2C1 | Intern. | 3 | 4 | 1 | 0 | 1 | no | no |
| 16 | 1017 | 0 | 0 | 1 | 0 | 0 | 0 | A0B1C0 | Not | 0 | 4 | 1 | 0 | 0 | no | no |
| 17 | 1095 | 2 | 1 | 3 | 0 | 0 | 0 | A1B2C0 | Low | 1 | 5 | 2 | 6 | 2 | NA | Caud. Thal Put |
| 18 | 1095 | 0 | 3 | 4 | 1 | 1 | 1 | A2B2C1 | Intern. | 0 | 5 | 2 | 0 | 0 | no | yes |
| 19 | 1050 | 0 | 3 | 1 | 1 | 1 | 1 | A1B1C1 | Low | 1 | 3 | 2 | 0 | 3 | yes, right | no |
| 20 | 1255 | 1.5 | 3 | 3 | 1 | 1 | 1 | A2B2C1 | Intern. | 1 | 5 | 3 | 0 | 0 | no | globus pallidus |
| 21 | 1105 | 1 | 2 | 3 | 1 | 1 | 1 | A1B2C1 | Low | 1 | 4 | 3 | 2 | 0 | no | yes |
| 22 | 1004 | 1 | 3 | 2 | 1 | 1 | 1 | A2B1C1 | Low | 1 | 4 | 2 | 0 | 0 | no | yes |
| 23 | 1185 | 1 | 4 | 4 | 1 | 1 | 1 | A3B2C1 | Intern. | 1 | 5 | 2 | 0 | 0 | no | no |

Supplementary Table S2. Continued (continued)

| No. | Brain weight [g] | Thal stage Aβ | | Braak & Braak stage NFTs | | Neuritic plaques (CERAD) | | AD neuro-pathologic change (NIA-Reagan) | | AD neuro-pathologic change (NIA-AA) | | Thal stage CAA | | Thal stage GVD | | Athero-sclerosis | | Braak stage Lewy bodies | | TDP-43 stage in AD | | Hippo-campal sclerosis | | ARTAG infarcts | | |
|-----|------------------|---------------|----|--------------------------|----|--------------------------|----|---|----|-------------------------------------|----|----------------|----|----------------|----|------------------|----|-------------------------|----|--------------------|----|------------------------|----|----------------|----|----|
| | | Atrophy (0-5) | 3 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 24 | 1110 | 0 | 3 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 25 | 1115 | 0 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 26 | 965 | 1 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 27 | 1320 | 0 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| 28 | 1155 | 0 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| 29 | 1150 | 0 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| 30 | 1145 | 0 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| 31 | 1135 | 0 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| 32 | 1130 | 0 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| 33 | 1355 | 1 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| 34 | 1115 | 2 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| 35 | 1200 | 1 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| 36 | 1055 | 1 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| 37 | 1190 | 1 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| 38 | 1060 | 2 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| 39 | 1160 | 0 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| 40 | 1145 | 0 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |

A β =amyloid beta. NFT=Neurofibrillary tangles. CAA=Cerebral amyloid angiopathy. GVD=Granulovacuolar degeneration. ARTAG=Aging-related tau astrogliopathy. CERAD=Consortium to establish a registry for Alzheimer's disease.

Supplementary Table S3a. Pearson correlation coefficient for the correlation plot in Figure 3.

| | Ability | | | | | | | | | | | | Braak | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|--|---------|-----------|-----------------|-----------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|-----|
| | MMSE | | | | VAT | | | | CDT | | | | Cogni- tive | | | | Brain | | | | Atrophy | | | | Athero- scler- osis | | | | Thal stage | | Thal stage | | CERAD | | Braak stage | | Thal stage | | pTDP-43 campal sclerosis | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Sex | Educ. [y] | Age at death | Bas. MMSE score | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas. MMSE at last visit | Bas |

Supplementary Table S3a. Pearson correlation coefficient for the correlation plot in Figure 3. (continued)

| | | VAT | | | | CDT | | | | Ability | | | | Braak | | | |
|--|--|---------------|--|--|--|-------------------------|--|--|--|--------------------|--|--|--|-------------|--|--|--|
| | | MMSE score | | | | score | | | | to | | | | stage | | | |
| | | at last visit | | | | Bas. CDT last visit | | | | com- plete testing | | | | for | | | |
| | | at last visit | | | | score | | | | impr. | | | | Lewy bodies | | | |
| | | at last visit | | | | MMSE at last visit | | | | weight | | | | Atrophy | | | |
| | | at last visit | | | | Bas. MMSE at last visit | | | | health | | | | Brain | | | |
| | | at last visit | | | | score | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | at last visit | | | | MMSE at last visit | | | | impr. | | | | weight | | | |
| | | | | | | | | | | | | | | | | | |

Supplementary Table S3b. P-values for the correlation plot in Figure 3.

| | Sex | Educ. [y] | Age at death | Bas. MMSE | MMSE score at last visit | VAT score at last visit | CDT score at last visit | Cognitive health | Brain weight | Atrophy | Lewy bodies | Atherosclerosis | Thal stage | Thal stage | CERAD score | Braak stage | Thal stage | Infarcts | pTDP-43 | Hippocampal sclerosis | | | | |
|-----------------------------|-------|-----------|--------------|-----------|--------------------------|-------------------------|-------------------------|------------------|--------------|---------|-------------|-----------------|------------|------------|-------------|-------------|------------|----------|---------|-----------------------|------|------|------|------|
| Sex | <.001 | .875 | .727 | .966 | .302 | .014 | .132 | .395 | .153 | .100 | .220 | .886 | >.99 | .093 | .556 | .637 | .873 | .836 | .578 | .551 | .221 | .515 | .588 | .030 |
| Educ. [y] | .875 | <.001 | .031 | .473 | .607 | .073 | .133 | .557 | .530 | .693 | .799 | .371 | .973 | .364 | .629 | .389 | .349 | .984 | .592 | .742 | .386 | .056 | .195 | .821 |
| APOEOR | .727 | .031 | <.001 | .128 | .646 | .273 | .368 | .167 | .437 | .351 | .352 | .249 | .876 | .455 | .777 | .806 | .024 | .335 | .649 | .139 | .484 | .576 | .235 | .610 |
| Age at death | .966 | .473 | .128 | <.001 | .402 | .302 | .148 | .380 | .442 | .287 | .005 | .415 | .224 | .803 | .470 | .279 | .996 | .368 | .580 | .791 | .085 | .597 | .189 | .085 |
| Bas. MMSE score | .302 | .607 | .646 | .402 | <.001 | <.001 | .005 | .276 | .049 | .063 | .001 | <.001 | .871 | .197 | .550 | .162 | .778 | .462 | .992 | .181 | .009 | .297 | .529 | .107 |
| MMSE score at last visit | .014 | .073 | .273 | .302 | <.001 | <.001 | .582 | .371 | .022 | .057 | .019 | <.001 | .690 | .705 | .526 | .070 | .909 | .493 | .956 | .164 | .032 | .076 | .611 | .024 |
| Bas. VAT score | .132 | .133 | .368 | .148 | .005 | .582 | <.001 | <.001 | .159 | .198 | .169 | .380 | .657 | .497 | .539 | .451 | .775 | .389 | .582 | .587 | .338 | .627 | .876 | .680 |
| VAT score at last visit | .395 | .557 | .167 | .380 | .276 | .371 | <.001 | <.001 | .176 | .392 | NA | .066 | .186 | .846 | .519 | .986 | .949 | .054 | .150 | .278 | .294 | .467 | .348 | .216 |
| Bas. CDT score | .153 | .530 | .437 | .442 | .049 | .022 | .159 | .176 | <.001 | <.001 | .601 | .107 | .268 | .288 | .311 | .918 | .010 | .242 | .221 | .036 | .032 | .212 | .967 | .697 |
| CDT score at last visit | .100 | .693 | .351 | .287 | .063 | .057 | .198 | .392 | <.001 | <.001 | .744 | .340 | .593 | .411 | .212 | .710 | .001 | .282 | .281 | .194 | .090 | .660 | .819 | .406 |
| Ability to complete testing | .220 | .799 | .352 | .005 | .001 | .019 | .169 | NA | .601 | .744 | <.001 | .005 | .777 | .072 | .916 | .845 | .892 | .277 | .365 | .469 | .024 | .639 | .583 | .001 |
| Cognitive health impr. | .886 | .371 | .249 | .415 | <.001 | <.001 | .380 | .066 | .107 | .340 | .005 | <.001 | .120 | .153 | .511 | .291 | .893 | .312 | .266 | .023 | .032 | .936 | .378 | .419 |
| Brain weight | >.99 | .973 | .876 | .224 | .871 | .690 | .657 | .186 | .268 | .593 | .777 | .120 | <.001 | .036 | .966 | .499 | .723 | .023 | .084 | .041 | .483 | .303 | .778 | .758 |
| Atrophy | .093 | .364 | .455 | .803 | .197 | .705 | .497 | .846 | .288 | .411 | .072 | .153 | .036 | <.001 | .022 | .234 | .058 | .767 | .961 | .269 | .926 | .244 | .774 | .421 |
| Braak stage for Lewy bodies | .556 | .629 | .777 | .470 | .550 | .526 | .539 | .519 | .311 | .212 | .916 | .511 | .966 | .022 | <.001 | .477 | .933 | .324 | .550 | .916 | .416 | .617 | .524 | .575 |
| Atherosclerosis | .637 | .389 | .806 | .279 | .162 | .070 | .451 | .986 | .918 | .710 | .845 | .291 | .499 | .234 | .477 | <.001 | .026 | .985 | .975 | .155 | .580 | .680 | .872 | .822 |
| Thal stage | .873 | .349 | .024 | .996 | .778 | .909 | .775 | .949 | .010 | .001 | .892 | .893 | .723 | .058 | .933 | .026 | <.001 | .003 | .021 | .069 | .241 | .775 | .392 | >.99 |
| CAA | .836 | .984 | .335 | .368 | .462 | .493 | .389 | .054 | .242 | .282 | .277 | .312 | .023 | .767 | .324 | .985 | .003 | <.001 | <.001 | .010 | .080 | .675 | .018 | .123 |

Supplementary Table S3b. P-values for the correlation plot in Figure 3. (continued)

| | Sex | Educ. [y] | APOE OR | Age at death | Bas. MMSE | MMSE at last visit | VAT score at last visit | VAT score at last visit | CDT score at last visit | Cognitive health | Brain weight | Atrophy | Lewy bodies | Atherosclerosis | Thal stage CAA | Thal stage Aβ | CERAD score | Braak stage NFT | Thal stage GVD* | Infarcts | pTDP-43 stage | Hippocampal sclerosis | | |
|-----------------------|------|-----------|---------|--------------|-----------|--------------------|-------------------------|-------------------------|-------------------------|------------------|--------------|---------|-------------|-----------------|----------------|---------------|-------------|-----------------|-----------------|----------|---------------|-----------------------|-------|-------|
| CERAD score | .578 | .592 | .649 | .580 | .992 | .956 | .582 | .150 | .221 | .281 | .365 | .266 | .084 | .961 | .550 | .975 | .021 | <.001 | <.001 | .014 | .128 | .901 | .034 | .045 |
| Braak stage | .551 | .742 | .139 | .791 | .181 | .164 | .587 | .278 | .036 | .194 | .469 | .023 | .041 | .269 | .916 | .155 | .069 | .010 | .014 | <.001 | <.001 | .131 | .502 | .729 |
| NFT | | | | | | | | | | | | | | | | | | | | | | | | |
| Thal stage | .221 | .386 | .484 | .085 | .009 | .032 | .338 | .294 | .032 | .090 | .024 | .032 | .483 | .926 | .416 | .580 | .241 | .080 | .128 | <.001 | <.001 | .040 | .471 | .408 |
| GVD* | | | | | | | | | | | | | | | | | | | | | | | | |
| Infarcts | .515 | .056 | .576 | .597 | .297 | .076 | .627 | .467 | .212 | .660 | .639 | .936 | .303 | .244 | .617 | .680 | .775 | .675 | .901 | .131 | .040 | <.001 | .360 | .752 |
| pTDP-43 stage | .588 | .195 | .235 | .189 | .529 | .611 | .876 | .348 | .967 | .819 | .583 | .378 | .778 | .774 | .524 | .872 | .392 | .018 | .034 | .502 | .471 | .360 | <.001 | .002 |
| Hippocampal sclerosis | .030 | .821 | .610 | .085 | .107 | .024 | .680 | .216 | .697 | .406 | .001 | .419 | .758 | .421 | .575 | .822 | >.99 | .123 | .045 | .729 | .408 | .752 | .002 | <.001 |

Bas.=Baseline. MMSE=Mini-Mental State Examination. VAT=Visual Association Test. CDT=Clock drawing test. CERAD=Consortium to establish a registry for Alzheimer's disease. CAA=Cerebral amyloid angiopathy. GVD=Granulovacuolar degeneration. AB=amyloid beta. NFT=Neurofibrillary tangles. APOE=Apolipoprotein.

Supplementary Table S3c. False discovery rates for the correlation plot in Figure 3. (continued)

| | Sex | Educ. level | APOE ε4 | Age at death | Bas. MMSE score | MMSE score | | | VAT | | | CDT Ability | | | Cognitive health impr. | Brain weight | Atrophy | Braak stage for Lewy bodies | Atherosclerosis | Thal stage | | Thal Aβ | CERAD score | | Braak stage NFT | Thal stage GVD* | Infarcts stage | | pTDP-43 stage | Hippocampal sclerosis |
|-----------------------|------|-------------|---------|--------------|-----------------|---------------|---------------|---------------|----------------|---------------|---------------|----------------|---------------|---------------|------------------------|--------------|---------|-----------------------------|-----------------|------------|-------|---------|-------------|------|-----------------|-----------------|----------------|------|---------------|-----------------------|
| | | | | | | at last visit | at last visit | at last visit | Bas. CDT score | at last visit | at last visit | Bas. CDT score | at last visit | at last visit | | | | | | CAA | score | | score | | | | | | | |
| CERAD score | .832 | .832 | .859 | .832 | >.99 | .999 | .832 | .561 | .832 | .561 | .641 | .693 | .743 | .693 | .405 | .999 | .832 | .832 | >.99 | .222 | <.001 | .222 | <.001 | .196 | .523 | .980 | .253 | .292 | | |
| Braak stage | .832 | .917 | .539 | .930 | .601 | .572 | .832 | .693 | .832 | .693 | .253 | .612 | .793 | .222 | .272 | .693 | .982 | .561 | .561 | .377 | .160 | .196 | <.001 | .002 | .523 | .808 | .907 | | | |
| NFT | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Thal stage | .641 | .743 | .797 | .405 | .155 | .246 | .743 | .694 | .743 | .694 | .246 | .422 | .222 | .246 | .797 | .987 | .752 | .832 | .832 | .663 | .398 | .523 | .523 | .002 | <.001 | .272 | .793 | .752 | | |
| GVD* | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Infarcts | .818 | .338 | .832 | .834 | .694 | .389 | .848 | .793 | .848 | .793 | .641 | .865 | .853 | .990 | .694 | .663 | .840 | .878 | .878 | .919 | .878 | .980 | .523 | .272 | <.001 | .743 | .919 | | | |
| pTDP-43 stage | .832 | .612 | .659 | .610 | .819 | .836 | .968 | .743 | .999 | .942 | .832 | .743 | .919 | .919 | .919 | .919 | .819 | .968 | .968 | .743 | .222 | .253 | .808 | .793 | .743 | <.001 | .044 | | | |
| Hippocampal sclerosis | .246 | .942 | .836 | .405 | .467 | .222 | .899 | .641 | .904 | .748 | .030 | .752 | .927 | .752 | .927 | .752 | .844 | .942 | .942 | >.99 | .511 | .292 | .923 | .748 | .927 | .044 | <.001 | | | |

Bas.=Baseline. MMSE=Mini-Mental State Examination. VAT=Visual Association Test. CDT=Clock drawing test. CERAD=Consortium to establish a registry for Alzheimer's disease. CAA=Cerebral amyloid angiopathy. GVD=Granulovacuolar degeneration. Aβ=amyloid beta. NFT=Neurofibrillary tangles. APOE=Apolipoprotein.